Loading...
XNAS
ENVB
Market cap3mUSD
May 20, Last price  
1.35USD
1D
-0.74%
1Q
-10.60%
IPO
-99.99%
Name

Enveric Biosciences Inc

Chart & Performance

D1W1MN
XNAS:ENVB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
80.24%
Rev. gr., 5y
20.09%
Revenues
0k
1,192,447333,201750,706000000015,976,42236,145,58948,593,71242,998,28039,914,67500000
Net income
-10m
-81,515-352,626807,276-143,636-58,544-39,441-33,380-24,621-161-33,644-1,890,758-2,780,686-9,074,813-16,897,516-5,603,975-6,386,945-48,976,896-18,471,3330-9,574,987
CFO
-8m
L-45.18%
-256,568-305,907329,928-150,186-65,041-40,666-30,346-24,850-21,632-43,164-3,671,622-2,703,989-2,740,794-2,565,495-2,453,123-3,888,785-11,457,671-17,146,723-14,094,411-7,726,139
Dividend
Apr 23, 20083.6981 USD/sh
Earnings
Aug 11, 2025

Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
URL
https://www.enveric.com/
IPO date
Jul 21, 2009
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
9,295
16,512
20,069
Unusual Expense (Income)
NOPBT
(9,295)
(16,512)
(20,069)
NOPBT Margin
Operating Taxes
(9)
29
(1,486)
Tax Rate
NOPAT
(9,286)
(16,541)
(18,583)
Net income
(9,575)
 
(18,471)
-62.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,374
(1,052)
17,222
BB yield
-1,871.90%
37.48%
-572.60%
Debt
Debt current
64
Long-term debt
64
Deferred revenue
Other long-term liabilities
527
Net debt
(2,241)
(2,288)
(17,596)
Cash flow
Cash from operating activities
(7,726)
(14,094)
(17,147)
CAPEX
(5)
(584)
Cash from investing activities
12
(584)
Cash from financing activities
7,674
(1,343)
18,180
FCF
(9,084)
(16,307)
(18,853)
Balance
Cash
2,241
2,288
17,724
Long term investments
Excess cash
2,241
2,288
17,724
Stockholders' equity
(106,662)
(97,042)
(78,839)
Invested Capital
108,255
98,998
94,459
ROIC
ROCE
EV
Common stock shares outstanding
503
2,159
1,446
Price
0.36
-72.43%
1.30
-37.50%
2.08
-95.53%
Market cap
180
-93.58%
2,807
-6.68%
3,008
-86.31%
EV
(2,061)
519
(13,704)
EBITDA
(9,126)
(16,104)
(19,634)
EV/EBITDA
0.23
0.70
Interest
4
5
Interest/NOPBT